Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD

This retrospective study focused on CD19-directed CAR T-cell therapy for patients with relapsed/refractory solid organ transplantation (SOT)-related post-transplant lymphoproliferative disorder (PTLD). Overall, one-third of patients achieved a sustained remission. The overall response rate was 64%, with a complete response rate of 55%. Cytokine release syndrome and/or immune effector cell-associated neurotoxicity syndrome were seen and their relationships with outcomes are discussed.